In this Healio Video Perspective from Hawaiian Eye 2025, Riad Sherif, MD, CEO of Oculis, discusses data on OCS-05 for the ...

The continued evolution of treatment protocols and imaging modalities for the management of retinal diseases ... age-related macular degeneration and diabetic macular edema. Upon successful ...

As a retina specialist, one of the most important aspects of eye care I focus on is the prevention and treatment of diabetic retinopathy. This condition is a leading cause of blindness in adults, yet ...

diabetic retinopathy, age-related macular degeneration, and glaucoma, and it is expected to become the mainstream method for ophthalmic OCT in the future (16, 17). This study compared retinal ...

State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China ...

IN the light-adapted state, the receptive fields of retinal ganglion cells in the cat consist of excitatory and inhibitory areas. Thus predominantly excitatory and inhibitory pathways converging ...

In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular edema ...

Diabetic macular edema remains an important cause of vision ... techniques. The Diabetic Retinopathy Clinical Research (DRCR) Network, which includes over 199 participating sites, is currently ...

EYE-103 is under clinical development by Eyebiotech and currently in Phase III for Diabetic Macular Edema. According to GlobalData, Phase III drugs for Diabetic Macular Edema have a 62% phase ...

and for the treatment of macular edema following central retinal vein occlusion. It is also indicated for non-proliferative diabetic retinopathy (NPDR), diabetic macular edema(DME) and Diabetic ...

Ocugen announced the first patient in its OCU200 phase 1 clinical trial for diabetic macular edema (DME ... targets the drug to the choroid and retina by binding transferrin receptors on endothelial ...

and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema ...